Screening for reactive intermediates and toxicity assessment in drug discovery

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 1, 2006, Pages 47-60

  Caldwell, Gary W ^a   Yan, Zhengyin ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cellular signaling processes; Covalent binding; CYP450 inhibition; Cytotoxicity; Glutathione detoxification; Idiosyncratic; In silico predictions; In vitro assays; Metabonomics; Reactive intermediates; Reactive metabolites

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASTEMIZOLE; CISAPRIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG; FREE RADICAL; GLUTATHIONE; MIBEFRADIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEFAZODONE; POTASSIUM CHANNEL HERG; REACTIVE OXYGEN METABOLITE; TERFENADINE; TROGLITAZONE;

AMES TEST; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; CARCINOGENICITY; CELL PROLIFERATION; CELL VIABILITY; CHO CELL; COLLISIONALLY ACTIVATED DISSOCIATION; COMPUTER MODEL; COVALENT BOND; DNA ADDUCT; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INHIBITION; DRUG METABOLISM; DRUG WITHDRAWAL; ELECTRON SPIN RESONANCE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER MICROSOME; LIVER TOXICITY; LYMPHOBLASTOID CELL LINE; MASS SPECTROMETRY; MUTAGENICITY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; QT INTERVAL; QT PROLONGATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TORSADE DES POINTES; TOXICITY TESTING; TUMOR XENOGRAFT;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; ENZYME INHIBITORS; FREE RADICALS; HUMANS; LIVER DISEASES; MAXIMUM TOLERATED DOSE; MICROSOMES, LIVER;

EID: 30744432123     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Humphrey MJ, Smith DA: Role of metabolism and pharmacokinetic studies in the discovery of new drugs - present and future perspectives. Xenobiotica (1992) 22(7):743-755. One of the first papers to discuss the role of metabolism and PK in the drug discovery process.
2. Welling PG: Role of pharmacokinetics in drug discovery and development Handbook of Experimental Pharmacology: Pharmacokinetics of Drugs. Welling PG, Balant LP (Eds), Springer-Verlag, Berlin, Germany (1994) 110:3-19.
3. Rodrigues AD: Use of in vitro human metabolism studies in drug development. An Industrial perspective. Biochem Pharmacol (1994) 48(12):2147-2156.
4. Welling PG: Changing status of pharmacokinetics in drug discovery and development. Int J Pharm Adv (1985) 1(2):121-133.
5. Caldwell J: The Importance of drug metabolism studies for efficient drug discovery and development. Yakubutsu Dotai (1996) 11(1):119-126.
6. Caldwell J: The role of drug metabolism in drug discovery and development: Opportunities to enhance time- and cost-efficiency. Pharm Sci (1998) 2:117-119.
7. Welling PG: Changes in pharmacokinetics and drug metabolism responsibility in drug discovery and development. Drugs Pharm Sci (1996) 76:261-279.
8. Humphrey MJ: Application of metabolism and pharmacokinetics studies to the drug discovery process. Drug Metab Rev (1996) 28(3):473-489.
9. Cashman JR: Drug discovery and drug metabolism. Drug Disc Today (1996) 1(5):209-216.
10. DiMasi JA: Risks, regulation and rewards in new drug development in the United States. Regul Toxicol Pharmacol (1994) 19(2):228-235.
11. DiMasi JA: Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther (1995) 58(1):1-14.
12. Kennedy T: Managing the drug discovery/development interface. Drug Disc Today (1997) 2(10):436-444.
13. Rodrigues AD: Preclinical drug metabolism in the age of high-throughput screening: An Industrial perspective. Pharm Res (1997) 14(11):1504-1510.
14. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv Drug Del Rev (1997) 23(1-3):3-25.
15. Rodrigues AD: Rational high-throughput screening in preclinical drug metabolism. Med Chem Res (1998) 8(7/8):422-433.
16. Tarit MH, Berman J: High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr Opin Chem Biol (1998) 2(3):411-416.
17. Smith DA: High-throughput drug metabolism. Biomed Health Res (1988) 25:137-143.
18. Sinko PJ: Drug selection in early drug development: Screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Curr Opin Drug Discovery Dev (1999) 2(1):42-48.
19. Watt AP, Morrison II, Evans DC: Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. Drug Disc Today (2000) 5(1):17-24.
20. Bertrand M, Jackson P, Walther B: Rapid assessment of drug metabolism in the drug discovery process. Eur J Pharm Sci (2000) 11:861-572.
21. White RE: High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol (2000) 40:133-157.
22. Caldwell GW: Compound optimization in early- and late-phase drug discovery: Acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. Curr Opin Drug Discovery Dev (2000) 3(1):30-41.
23. Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Yan Z: The new pre-preclinical paradigm: Compound optimization in early and late phase drug discovery. Curr Topics Med Chem (2001) 1(5):353-366.
24. Roberts SA: High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica (2001) 31(8-9):557-589.
25. Chaturvedi PR, Decker CJ, Odinecs A: Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr Opin Chem Biol (2001) 5(4):452-463.
26. Cox KA, Clarke NJ, Rindgen D, Korfmacher WA: Higher throughput metabolite identification in drug discovery: Current capabilities and future trends. American Pharma Rev (2000) 4(1):45-52.
27. Cox KA, White RE, Korfmacher WA: Rapid determination of pharmacokinetic properties of new chemical entitles: In vivo approaches. Comb Chem High Throughput Screen (2002) 5(1):29-37.
28. Riley RJ, Martin IJ, Cooper AE: The influence of DMPK as an integrated partner in modern drug discovery. Curr Drug Metab (2002) 3(5):527-550.
29. Selick HE, Beresford AP, Tarbit MH: The emerging importance of predictive ADME simulation in drug discovery. Drug Disc Today (2002) 7(2):109-116.
30. Smith D, Schmid E, Jones B: Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery? Clin Pharmacokinet (2002) 41(13):1005-1019.
31. Caldwell GW, Yan Z, Masucci JA, Hageman W, Leo G, Ritchie DM: Applied pharmacokinetic in drug development: An overview of drug discovery. Pharm Dev Regul (2003) 1(2):117-132.
32. Roberts SA: Drug metabolism and pharmacokinetics in drug discovery. Curr Opin Drug Discovery Dev (2003) 6(1):66-80.
33. Kerns EH, Di L: Pharmaceutical profiling in drug discovery. Drug Disc Today (2003) 8(7):316-323.
34. Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, Barbosa F, Migeon JC: Predicting ADME properties and side effects: The BioPrint approach. Curr Opin Drug Discovery Dev (2003) 6(4):470-480.
35. Huebert ND, Dasgupta M, Chen Y: Using in vitro human tissues to predict pharmacokinetic properties. Curr Opin Drug Discovery Dev (2004) 7(1):69-74.
36. White RE: A comprehensive strategy for ADME screening in drug discovery. Biotech: Pharm Aspects (2004) 1:431-450.
37. Gudmundsson OS, Venkatesh, SL: Strategies for in silico and experimental screening of physicochemical properties. Biotech: Pharm Aspects (2004) 1:393-412.
38. Saunders KC: Automation and robotics in ADME screening. Drug Disc Today: Technology (2004) 1(4):373-380.
39. Kerns EH, Di L: Physicochemical profiling: Overview of the screens. Drug Disc Today: Technology (2004) 1(4):343-348.
40. Caldwell GW, Ritchie DM: Is early absorption screening useful in the selection of drug candidates? Preclinica (2004) 2(6):399-401.
41. Ette EI, Garg V, Jayaraj A: Drug development A rational approach. In: Pharmacokinetics in Drug Development: Regulatory and Development Paradigms. Bonate PL, Howard DR (Eds), American Association of Pharmaceutical Scientists, Arlington, VA, USA (2004) 2:3-36.
42. Yan Z, Caldwell GW (Eds): Optimization in Drug Discovery: In Vitro Methods. Humana Press, Totowa, NJ, USA (2004).
43. Gomez-Orellana I: Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv (2005) 2(3):419-433.
44. Korfmacher WA (Ed): Using Mass Spectrometry for Drug Metabolism Studies. CRC Press LLC, Boca Raton, FL, USA (2005).
45. Kaplita PV, Hu H, Liu L, Farrell TM, Grbic H, Spero DM: Automatable formats of higher throughput ADMET profiling for drug discovery support J Assoc Lab Auto (2005) 10(3):140-148.
46. Van de Waterbeemd H: Which in vitro screens guide the prediction of oral absorption and volume of distribution? Basic Clin Pharmacol Toxicol (2005) 96(3):162-166.
47. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 3(8):711-715.
48. Littman BH, Williams SA: The ultimate model organism: Progress in experimental medicine. Nat Rev Drug Discov (2005) 4(8):631-638.
49. Suggitt M, Bibby MC: 50 Years of preclinical anticancer drug screening: Empirical to target-driven approaches. Clin Cancer Res (2005) 11(3):971-981.
50. Jonas S, Aiyagari V, Vieira D, Figueroa M: The failure of neuronal protective agents versus the success of thrombolysis in the treatment of ischemic stroke: The predictive value of animal models. Ann NY Acad Sci (2001) 939:257-267.
51. Wiendl H, Hohlfeld R: Therapeutic approaches in multiple sclerosis. Lessons from failed and interrupted treatment trials. BioDrugs (2002) 16(3):183-200.
52. Ikonomidou C, Turski L: Why did NMDA receptor antagonists fall clinical trials for stroke and traumatic brain injury? Lancet Neurology (2002) 1(6):383-386.
53. Raymond GH: Can the evaluation of drugs in animal pain models reliably predict the ability to produce clinical analgesia? Prog Pain Res Manage (2004) 31:247-258.
54. Johnson DE, Wolfgang GH: Assessing the potential toxicity of new pharmaceuticals. Curr Top Med Chem (2001) 1(4):233-245.
55. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol (2000) 32(1):56-67.
56. Fermini B, Fossa AA: Preclinical assessment of drug-induced QT interval prolongation. Current issues and impact on drug discovery. Annu Reports Med Chem (2004) 39:323-334.
57. Guo L, Guthrie H: Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Methods (2005) 62(1):123-135.
58. Hammond TG, Pollard CE: Use of in vitro methods to predict QT prolongation. Toxicol Appl Pharmacol (2005) 207(2 Suppl):446-450.
59. Finlayson K, Witchel HJ, McCulloch J, Sharkey J: Acquired QT interval prolongation and HERG: Implications for drug discovery and development. Eur J Pharmacol (2004) 500(1-3):129-142.
60. Park K, Williams DP, Naisbitt DJ, Kitteringham NR, Pirmohamed M: Investigation of toxic metabolites during drug development. Toxicol Appl Pharmacol (2005) 207(2 Suppl):425-434.
61. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP: The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol (2005) 48:177-202.
62. Walgren JL, Mitchell MD, Thompson DC: Role of metabolism in drug-induced idiosyncratic hepatotoxiclty. Crit Rev Toxicol (2005) 36(4):325-361. Provides an excellent review of the current evidence in support of reactive intermediates and their role in idiosyncratic hepatotoxicity.
63. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA: Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem Res Toxicol (2004) 17(1):3-16.
64. Uetrecht J: Current trends in drug-induced autoimmunity. Autoimmun Rev (2005) 4(5):309-314.
65. Uetrecht J: Role of drug metabolism for breaking tolerance and the localization of drug hypersenstivity. Toxicology (2005) 209(2):113-118.
66. Kirkland D, Aardema M, Henderson L, Mueller L: Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat Res (2005) 584(1-2):1-256.
67. Xu JJ, Diaz D, O'Brien PJ: Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact (2004) 150(1):115-128.
68. Nassar AE, Lopez-Anaya A: Strategies for dealing with reactive intermediates in drug discovery and development. Curr Opin Drug Discovery Dev (2004) 7(1):126-136.
69. Nassar AE, Kamel AM, Clarimont C: Improving the decision-making process in structural modification of drug candidates: Reducing toxicity. Drug Disc Today (2004) 9(24):1055-1064.
70. Colmenarejo G: In silico ADME prediction: Data sets and models. Curr Computer-Aided Drug Des (2005) 1(4):365-376.
71. Van de Waterbeemd H: From in vivo to in vitro/in silico ADME: Progress and challenges. Expert Opin Drug Metab Toxicol (2005) 1(1):1-4.
72. Narayanan R, Gunturi SB: In silico ADME modelling: Prediction models for blood-brain barrier permeation using a systematic variable selection method. Bioorg Med Chem (2005) 13(8):3017-3028.
73. Helma C: In silico predictive toxicology: The state-of-the-art and strategies to predict human health effects. Curr Opin Drug Discovery Dev (2005) 8(1):27-31.
74. Yamashita F, Hashida M: In silico approaches for predicting ADME properties of drugs. Drug Metab Pharmacokinet (2004) 19(5):327-338. Summarizes the most practical in silico ADME approaches.
75. Greene N, Judson PN, Langowski, JJ, Marchant CA: Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ Res (1999) 10(2-3):299-314.
76. Balmat A-L, Judson P, Long A, Testa B: Predicting drug metabolism - an evaluation of the expert system METEOR. Chem Biodivers (2005) 2(7):872-885.
77. Ekins S: In silico approaches to predicting drug metabolism, toxicology and beyond. Structural Biol Drug Metab Drug Disc (2003) 31(3):611-614.
78. Judson PN, Cooke PA, Doerrer NG, Greene N, Hanzlik RP, Hardy C, Hartmann A, Hinchlifle D, Holder J, Mueller L, Steger-Hartmann T et al: Towards the creation of an international toxicology information centre. Toxicology (2005) 213(1-2):117-128.
79. O'Brien SE, De Groot MJ: Greater than the sum of its parts: Combining models for useful ADMET prediction. J Med Chem (2005) 48(4):1287-1291.
80. Farkas D, Tannenbaum SR: In vitro methods to study chemically induced hepatotoxicity: A literature review. Curr Drug Metab (2005) 6(2):111-125.
81. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab (2005) 6(3):161-225.
82. Yan Z, Caldwell GW: Metabolism profiling and cytochrome P450 inhibition and induction in drug discovery. Curr Top Med Chem (2001) 1(5):403-425.
83. Baillie TA, Davis MR: Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrum (1993) 22(6):319-325.
84. Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP, Dean DC, Pang J, Leung KH, Doss GA, Strauss JR et al: Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: Identification of glutathione conjugated metabolites. Drug Metab Dispos (1999) 27(3):365-372.
85. Castro-Perez J, Plumb R, Liang L, Yang E: A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Commun Mass Spectrom (2005) 19(6):798-804.
86. Yan Z, Caldwell GW: Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. Anal Chem (2004) 76(23):6835-6847.
87. Yan Y, Maher N, Torres R, Caldwell GW, Huebert N: Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry. Rapid Comm Mass spectrometry (2005) 19(22):3322-3330.
88. Yan Z, Zhong HM, Maher N, Torres R, Leo GC, Caldwell GW, Huebert N: Bioactivation of 4-methylphenol (p-cresol) via cytochrome-P450-mediated aromatic oxidation in human liver microsomes. Drug Metab Dispos (2005) 33(12):1867-1876.
89. Yan Z, Li J, Huebert N, Caldwell GW, Du Y, Zhong H: Detection of a novel reactive metabolite of diclofenac: Evidence for CYP2C9-mediated bioactivation via arene oxides. Drug Metab Dispos (2005) 33(6)706-713.
90. Soglia JR, Harriman SP, Zhao S, Barberia J, Cole MJ, Boyd JG, Contillo LG: The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathlone ethyl ester as an in vitro conjugating agent. J Pharm Biomed Anal (2004) 36(1):105-116.
91. Gan J, Harper TW, Hsueh M-M, Qu Q, Humphreys WG: Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem Res Toxicol (2005) 18(5):896-903.
92. Zhu M, Zhao W, Vazquez N, Mitroka JG: Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: Method validation and application. J Pharm Biomed Anal (2005) 39(1-2):233-245.
93. Samuel K, Yin W, Stearns RA, Tang YS, Chaudhary AG, Jewell JP, Lanza T Jr, Lin LS, Hagmann WK, Evans DC, Kumar S: Addressing the metabolic activation potential of new leads in drug discovery: A case study using ion trap mass spectrometry and tritium labeling techniques. J Mass Spectrom (2003) 38(2):211-221.
94. Wang T, Abbott FS: A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its α-fluorinated analog: Phase II metabolism and pharmacokinetics. Drug Metab Dispos (1997) 25(2):219-227.
95. Shetty HU, Nelson WL: Attempts to use cyanide ion to trap imine intermediates in the microsomal N-dealkylation of propranolol: Formation of α-aminonitriles as artifacts when using ether for extraction. J Pharm Sci (1985) 74(9):968-971.
96. 14C-sodium cyanide during microsomal oxidation. Adv Exp Med Biol (1991) 283:657-664.
97. Gorrod JW, Aislaitner G: The metabolism of alicyclic amines to reactive iminium ion intermediates. Eur J Drug Metab Pharmacokinet (1994) 19(3):209-217.
98. Argoti D, Liang L, Conteh A, Chen L, Bershas D, Yu C-P, Vouros P, Yang E: Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem Res Toxicol (2005) 18(10):1537-1544.
99. Yan Z, Rafferty B, Caldwell GW, Masucci JA: Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses. Eur J Drug Metab Pharmacokinet (2002) 27(4):281-287.
100. Naritomi Y, Teramura Y, Terashita S, Kagayama A: Utility of microtiter plate assays for human cytochrome P460 inhibition studies in drug discovery: Application of simple method for detecting quasi-irreversible and irreversible inhibition. Drug Metab Pharmacokinet (2004) 19(1):55-61.
101. Liu KJ, Kotake Y, Lee M, Miyake M, Sugden K, Yu Z, Swartz HM: High-performance liquid chromatography study of the pharmacokinetics of various spin traps for application to in vivo spin trapping. Free Radic Biol Med (1999) 27(1-2):82-89.
102. Dikalova AE, Kadiiska MB, Mason RP: An in vivo ESR spin-trapping study: Free radical generation in rats from formate intoxication-role of the Fenton reaction. Proc Natl Acad Sci USA (2001) 98(24):13549-13553.
103. Qian SY, Kadiiska MB, Quo Q, Mason RP: A novel protocol to identify and quantify all spin trapped free radicals from in vitrolin vivo interaction of HO· and DMSO: LC/ESR, LC/MS and dual spin trapping combinations. Free Radic Biol Med (2005) 38(1):125-135.
104. Miyamoto Y, Koh YH, Park YS, Fujiwara N, Sakiyama H, Misonou Y, Ookawara T, Suzuki K, Honke K, Taniguchi N: Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol Chem (2003) 384(4):567-574.
105. Lautraite S, Bigot-Lasserre D, Bars R, Carmichael N: Optimization of cell-based assays for medium throughput screening of oxidative stress. Toxicol Vitro (2003) 17(2):207-220.
106. Bombick DW, Dodittle DJ: A fluorescent method for the measurement of intracellular hydroparoxides in living mammalian cells. Toxicol Methods (1992) 2(4):255-264.
107. Pani G, Colavitti R, Bedogni B, Anzevino R, Borrello S, Galeotti T: Determination of intracellular reactive oxygen species as function of cell density. Methods Enzymol (2002) 352:91-100.
108. Loetchutinat C, Kothan S, Dechsupa S, Meesungnoen J, Jay-Gerin J-P, Mankhetkom S: Spectrofluorometric determination of intracellular levels of reactive oxygen species in drug-sensitive and drug-resistant cancer cells using the 2′,7′-dichlorofluorescein diacetate assay. Radiat Phys Chem (2005) 72(2-3):323-331.
109. Eklund BI, Edalat M, Stenberg G, Mannervik B: Screening for recombinant glutathione transferases active with monochlorobimane. Anal Biochem (2002) 309(1):102-108.
110. Stevenson D, Wokosin D, Girkin J, Grant MH: Measurement of the intracellular distribution of reduced glutathione in cultured rat hepatocytes using monochlorobimane and confocal laser scanning microscopy. Toxicol Vitro (2002) 16(5):609-619.
111. Bratosin D, Mitrofan L, Palii C, Estaquier J, Montreuil J: Novel fluorescence assay using calcein-AM for the determination of human erythrocyte viability and aging. Cytometry Pt A (2005) 66A(1):78-84.
112. Uggeri J, Gatti R, Belletti S, Scandroglio R, Corradini R, Rotoli BM, Orlandini G: Calcein-AM is a detector of intracellular oxidative activity. Histochem Cell Biol (2004) 122(5):499-505.
113. Schoonen WG, de Roos JA, Westerink WM, Debiton E: Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. Toxicol Vitro (2005) 19(4):491-503.
114. Day SH, Mao A, White R, Schulz-Utermoehl T, Miller R, Beconi MG: A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol Toxicol Methods (2005) 52(2):278-285.
115. 32P-Postlabeling assay for the quantification of the major platinum-DNA adducts. Anal Biochem (1999) 275(1):30-38.
116. 32P-Analysis of DNA adducts in somatic and reproductive tissues of rats treated with the anticancer antibiotic, mitomycin C. Mutat Res (1987) 179(1):75-88.
117. 32P-Postlabeling/ polyacrylamide gel electrophoresis analysis: Application to the detection of DNA adducts. Chem Res Toxicol (2002) 15(3):305-311.
118. Shibutani S, Suzuki N, Laxmi YR, Schild LJ, Divi RL, Grollman AP, Poirier MC: Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res (2003) 63(15):4402-4406.
119. Maron DM, Ames BN: Revised methods for the Salmonella mutagenicity test. Mutat Res (1983) 113(3-4):173-215.
120. Fluckiger-Isler S, Baumeister M, Braun K, Gervais V, Nguyen-Hasler N, Reimann R, Van Gompel J, Wunderlich H-G, Engelhardt G: Assessment of the performance of the Ames II assay: A collaborative study with 19 coded compounds. Mutat Res (2004) 558(3):181-197.
121. Hakura A, Shimada H, Nakajima M, Sui H, Kitamoto S, Suzuki S, Satoh T: Salmonella/human S9 mutagenicity test: A collaborative study with 58 compounds. Mutagenesis (2005) 20(3):217-228.
122. Applegate ML, Moore MM, Broder CB, Burrell A, Juhn G, Kasweck KL, Lin PF, Wadhams A, Hozier JC: Molecular dissection of mutations at the heterozygous thymidine kinase locus in mouse lymphoma cells. Proc Natl Acad Sci USA (1990) 87(1):51-55.
123. Pirmohamed M, Park BK: Metabolic models of cytotoxicity. In: Handbook of Drug Metabolism. Woolf TF (Ed), Marcel Dekker Inc, New York, NY, USA (1999):443-476.
124. Huong PL, Kolk AH, Eggelte TA, Verstijnen CP, Gilis H, Hendriks JT: Measurement of antigen specific lymphocyte proliferation using 5-bromodeoxyuridine incorporation. An easy and low cost alternative to radioactive thymidine incorporation. J Immunol Methods (1991) 140(2):243-248.
125. Penketh PG, Shyam K, Sartorelli AC: Fluorometric assay for the determination of DNA-DNA cross-links utilizing Hoechst 33258 at neutral pH values. Anal Biochem (1997) 252(1):210-213.
126. York JL, Maddox LC, Zimniak P, McHugh TE, Grant DF: Reduction of MTT by glutathione S-transferase. BioTechniques (1998) 25(4):626-628.
127. Mikus J, Steverding D: A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye alamar blue. Parasitol Int (2000) 48(3):265-269.
128. Klein CL, Wagner M, Kirkpatrick CJ, Van Kooten TG: A new quantitative test method for cell proliferation based on detection of the KI-67 protein. J Mater Science: Mater Med (2000) 11(2):125-132.
129. McMillian MK, Grant ER, Zhong Z, Parker JB, Li L, Zivin RA, Burczynski ME, Johnson MD: Nile red binding to HepG2 cells: An Improved assay for in vitro studies of hepatosteatosis. In Vitro Mol Toxicol (2001) 14(3):177-190.
130. Allison DC, Ridolpho P: Use of a trypan blue assay to measure the deoxyribonucleic acid content and radioactive labeling of viable cells. J Histochem Cytochem (1980) 28(7):700-703.
131. Andreu N, Gibert I, Luquin M, Kolattukudy PE, Sirakova T: Neutral red staining of cells of a sulfolipid-deficient Mycobacterium tuberculosis pks2 mutant proves that sulfolipids are not responsible for this cytochemical reaction. J Clin Microbiol (2004) 42(3):1379-1380.
132. Lobner D: Comparison of the LDH and MTT assays for quantifying cell death: Validity for neuronal apoptosis? J Neurosci Methods (2000) 96(2):147-152.
133. Riss TL, Moravec RA: Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev Technol (2004) 2(1):51-62.
134. Lee WM: Drug-induced hepatotoxicity. N Engl J Med (2003) 349(5):474-485. Provides an excellent mechanistic overview of hepatotoxicity.
135. Dambach DM, Andrews BA, Moulin F: New technologies and screening strategies for hepatotoxicity: Use of in vitro models. Toxicol Pathol (2005) 33(1):17-26. Presents data for a highly useful hepatotoxicity screen.
136. Mortin LI, Horvath CJ, Wyand MS: Safety pharmacology screening: Practical problems in drug development. Int J Toxicol (1997) 16(1):41-65.
137. Luft J, Bode G: Integration of safety pharmacology endpoints into toxicology studies. Fundam Clin Phamacol (2002) 16(2):91-103.
138. Redfern WS, Wakefield ID, Prior H, Pollard CE, Hammond TG, Valentin J-P: Safety pharmacology - a progressive approach. Fundam Clin Pharmacol (2002) 16(3):161-173.
139. Bass A, Kinter L, Williams P: Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods (2004) 49(3):145-151.
140. Whitebread S, Hamon J, Bojanic D, Urban L: Keynote review: in vitro safety pharmacology profiling: An essential tool for successful drug development. Drug Disc Today (2005) 10(21):1421-1433.
141. McMillian M, Nie AY, Parker JB, Leone A, Bryant S, Kemmerer M, Herlich J, Liu Y, Yieh L, Bittner A, Liu X et al. A gene expression signature for oxidant stress/reactive metabolite in rat liver. Biochem Pharmacol (2004) 68(11):2249-2261.
142. McMillian M, Nie A, Parker JB, Leone A, Kemmerer M, Bryant S, Herlich J, Yieh L, Bittner A, Liu X, Wan J et al: Drug-induced oxidative stress in rat liver from a toxicogenomics perspective. Toxicol Appl Pharmacol (2005) 207(2 Suppl):171-178.
143. Nicholson JK, Connelly J, Lindon JC, Holmes E: Metabonomics: A platform for studying drug toxicity and gene function. Nat Rev Drug Discov (2002) 1(2):153-161. Provides an excellent overview of NMR-based metabonomics as a tool in drug discovery.
144. Griffin JL: Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterization of xenobiotics toxicity and disease diagnosis. Curr Opin Chem Biol (2003) 7(5):648-654.
145. Halket JM, Przyborowska A, Stein SE, Mallard WG, Down S, Chalmers RA: Deconvolution of gas chromatograph/mass spectrometry of urinary organic acids - potential for pattern recognition and automated identification of metabolic disorders. Rapid Commun Mass Spectrom (1999) 13(4):279-284.
146. Shen Y, Zhang R, Moore RJ, Kim J, Metz TO, Hixson KK, Zhao R, Livesay EA, Udseth HR, Smith RD: Automated 20 kpsi RPLC-MS and MS/MS with chromatographic peak capacities of 1000-1500 and capabilities in proteomics and metabolomics. Anal Chem (2005) 77(10):3090-3100.
147. Shockcor JP, Holmes E: Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem (2002) 2(1):35-51.